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Many factors, such as differences in bone marrow processing procedures, staining, degree of skill in interpretation and terminology used, contribute to a lack of standardization of this diagnostic tool.
However, the new WHO classification highlights the importance of morphological aspects, quantitative as well as qualitative, for the recognition of disease entities and better stratification of patients with hematological neoplasms, particularly myeloid neoplasms and above all myelodysplastic syndromes (MDS). Evaluation of blood and bone marrow cytology is, together with bone marrow biopsy morphology, immunophenotyping and cytogenetics, a very important step in the integrated diagnostic process of hematological diseases.
The current information and communication technology (ICT) era provides the opportunity to exchange, via internet, images and information without geographic limitation, saving time and resources. In the field of hematology, many studies highlight the robustness of ICT for diagnostic assessment of blood cells [1] [2] [3] [4] . ICT is therefore well suited to pursue a full consensus in the assessment of cell morphology.
The European LeukemiaNet (ELN, www.leukemia-net.org) Network of Excellence is an EU project funded by the 6 th Framework Programme and includes 162 participating centers in 33 countries, with more than 1000 researchers and associates. Its major goal is the construction of a cooperative network for improving leukemia diagnosis, care and research. The ELN Morphology 
Design and Methods
This study was carried out in three consecutive steps, aimed to take advantage of individual competences, to train each other, and to reach a full consensus by the end of the study.
During all the phases of the study, all files containing cell names were analysed without knowledge of the identity of the faculty member from whom images originated.
Statistical analyses were performed with the MEDCALC statistical software (Mariakerke, Belgium).
First phase of the study
To test the methodology, 50 images with 139 consecutively numbered cells were provided by the chair of the EMF and uploaded onto a restricted web page in June 2007. A database containing name proposals (including alternative glossary options) for each labelled cell in terms of lineage and maturation stage, was sent to all EMF members. The initial lineage/morphological categories were: erythroid, granulocytic, lymphoid, megakaryocytic, monocytic, blast and "other". Monocytes were included into separate category, since atypical cells of the monocytic series still remain the most difficult to identify in PB and BM specimens both in health and disease [5] [6] [7] . Participating members were asked to indicate in the Excel file whether they agreed with proposed terminology or give an alternative definition for each labelled cell. After all answers had been collected, a preliminary version of a consensual ELN Blood Cells Glossary (EBCG) of morphological terms was created.
Each EMF member was then asked to provide at least 5 meaningful images of cells together with the proposed cell definition(s) in terms of lineage and maturation stage, with the possibility of a second option. It was specifically requested to use, when available, nomenclature from the preliminary version of the EBCG . 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w At this phase, the Faculty was composed of 21 members and each cell definition was considered approved if agreement from at least 17 members was obtained, corresponding to a consensus of over 80%.
Delphi method
The Delphi technique [8] [9] [10] is based on the Hegelian principle of achieving oneness of mind through a 3-step process of thesis, antithesis and synthesis. In thesis and antithesis all participants present their opinion on a given subject and views and opposing views are established. In practice, it is a structured process based on the collection of knowledge from a group of experts and rounds of examination of proposals/questionnaires until consensus is obtained. The methodology has been previously applied in several clinical studies, including attempts to obtain consensus in histopathology 11 . Delphi methodology was applied to the next step of our study to obtain better consensus for cells without a full agreement (<17/21) during the first round of answers. As a prerequisite, one alternative term had to have been proposed by at least 3 members to be included into the options of the Delphi questionnaire. Moreover, cells with a full agreement (≥17/21) but with a different classification provided by at least 3/21 members were also submitted to the Delphi questionnaire, in order to discuss as many different options as possible.
For this phase of the study, a new database was prepared, in which all cells without full agreement were listed with the proposed two or three options for terminology. For each option, the rate of initial agreement was indicated as the number of faculty members in agreement. It was then proposed to score each option between 3 and 1, with 3 = full agreement, 2 = partial agreement, 1=
full disagreement. Score 3 could be used only for one single option for each cell.
Data were then summarized and a new Delphi round was performed for those cells presenting with a low final score (<7) resulting from at least 2 full agreements. a set of two new images without providing cell names. Participants were asked to name each of the submitted cells using cell definitions from the EBCG, whenever possible. The aim of this phase was to evaluate the level of consensus reached by the EMF after the first training round of the study. All data were collected, grouped and analysed with the same requirement of at least 80% agreement for definite term used for a given cell.
Second phase of the study

Third phase of the study
In October 2008 during a two-day meeting in Nancy, we collectively reviewed i) the set of 79 cells with a scoring difference <7 between two options after the first Delphi round and ii) the set of 98 not fully agreed cells submitted in the second phase without providing any cell name. Aims of this phase of the study were to reach the highest possible consensus before uploading images onto the ELN web site, to discuss and possibly find a consensus on all the problems faced during the process, and to finally agree on the ELN Cell Glossary.
Results
One-hundred and sixty-four images containing 438 labelled blood cells were initially collected from the EMF members with the submitter's proposal(s) of term(s) for each labelled cell. The celllineage distribution, according to the submitter's proposal was: granulocytic series 126 (29%), erythroid series 77 (17.5%), monocytic series 35 (8%), lymphoid series 107 (24.5%), megakaryocytic series 23 (5.5%), blasts 29 (6.5%) and "other" 41 (9.5%). During this primary evaluation, a full consensus (≥ 17/21) was achieved for 250 cells (59.4%). The preliminary version of the EBCG was prepared. Major discrepancies in morphological consensus concerned the groups of blasts and monocytic series (Table 1) . Another important discrepancy was due to difference between the EBCG and the Anglo-American hematology experts concerning the terms used to identify the differentiation stages of the erythroid series. In order to harmonize the EBCG, we decided to add whenever necessary the alternative denomination in brackets, i.e. "erythroblast basophilic (early erythroblast)". After discussion and review of the pictures, the EMF created a new category, "Cell to delete", for a set of 8 cells, since disagreement or, more precisely, failure to reach a firm decision, was mostly due to the poor quality of the images. Table 2 shows the subgroup partition of submitted cells before and after the Delphi round. After the Delphi round the full agreement (lineage, cell differentiation level, normal vs dysplastic feature) was reached on all of the 216 submitted cells and the list of EBCG could be implemented.
Seventy-nine cells, showing a scoring difference <7 between two options (resulting from two full agreements or three partial agreements) were listed to be discussed during the consensus meeting. Disagreement involved two major aspects: semantic problems and cell identification.
Many of the semantic problems were solved before the meeting, exchanging comments via internet and adopting the agreed EBCG. The discussion of additional issues, such as limitation of microscopic evaluation alone to define a lymphocyte as atypical or reactive, was further carried on at the consensus meeting. One of the semantic concerns involved the term which had to be used to identify a "morphologically abnormal" plasma cell: atypical or dysplastic. Another question which had to be discussed collectively was if the term "dysplastic" should be used only for the three myeloid lineages (granulocytic, erythroid, megakaryocytic) or not.
With regard to cell identification, the majority of discrepancies concerned the decision if cells should be considered normal or dysplastic. That problem was found in 2 cells of the (Table 3 ).
In the second phase of the study, 64 new images with 162 labelled cells were collected: cells were re-labelled from number 439 to 600 to follow the sequence of the previous set and uploaded onto the restricted web page without any cell name proposal: EMF participants were asked to name the should be underlined that in this phase of the study, cells were submitted without a name proposal, as for the first phase of this study. The remaining 102 cells were collectively discussed, agreed upon and named during the two-day meeting (Table 4) . Three additional cells were deleted, due to the poor quality of the images. During the interactive discussion on the images, the EMF decided to label 4 more cells because of their relevance in the context (1 blast NOC, 1 promyelocyte, 1 promonocyte and 1 megakaryoblast, respectively) and to add the category "Cytologically unclassifiable" for 5 images displaying metastatic cells, previously included in the category "other".
The ECBG was updated.
Major discrepancies on this set of cells concerned the appropriate use of terms such as dysplasia, atypical or Mott cell. All the problems faced and all the points discussed were listed: a Consensus statement document was approved: all the points are highlighted in the Discussion section. At the end of the meeting 228 images with 604 labelled blood cells were available to be uploaded onto the European LeukemiaNet website http://www.leukemia-net.org under the section Diagnostic WP10, together with an Excel file (ECBG) where each cell is identified by its code, the type of stain used, the lineage and the consensus name agreed by the EMF. All this material is currently freely available on the ELN web site and is linked to the EHA web site (http://ehaweb.org) under the section >Education/distance training/ morphology database<.
The EMF decided to highlight the cells agreed after the Delphi round and/or the meeting in Nancy, with a round red circle around the ID number, to point out all the problems discussed during this project.
A set of 239 cells without the ID agreed by the Faculty, was submitted via internet to a recognized expert morphologist (JMB) external to the EFM: after the first round, he rejected 34 cells as not 
Discussion and consensus statement
This manuscript describes the methodology used to develop a consensual glossary for the denomination of hematopoietic cells within the European LeukemiaNet "diagnostics" workpackage.
This highly interactive work was made possible through the use of modern communication means, and required only one two-day meeting of actual confrontation and debate. It resulted in the production of a freely accessible tool that could be useful for training as well as harmonization of morphological reports in oncohematology especially, without geographic limitation (i.e., not limited to European countries).
Significant omissions in the archive should be identified in the future and contributions should be sought for inclusion after validation.
Moreover, this collective work resulted in the production of a consensus statement as summarized below, taking into account individual practices, collegial agreement and literature data.
1-In building a photographic archive it is essential to use well stained films and to select cells in a part of the film that is not too thick. Precise focus and a high enough power to clearly assess cellular details are essential. The stain used should be specified only if it was not a MayGrünwald-Giemsa or similar Romanowsky-type stain. The magnification should not be stated 2-When significant extra information that makes the photograph more informative is available, this should be added. When brief information is sufficient it should be provided in brackets, e.g. erythroblast, vacuolated (alcohol excess). 6-Dysplasia is a description of morphologically abnormal development and is not synonymous with myelodysplastic syndromes (MDS).
7-
The term 'dysplastic' should only be used for the three myeloid lineages. For cells of other lineages showing similar morphologically abnormal development, e.g. lymphocytes and plasma cells the convention of using the term 'atypical' should be followed. Despite their myeloid nature, the convention of applying 'atypical' also to mast cells is supported.
8-Dysplastic hemopoiesis can lead to the production of cytologically abnormal erythrocytes (e.g. poikilocytes or a dimorphic population) or platelets (e.g. giant, hypogranular or with abnormal granules); however the term 'dysplasia' should be confined to nucleated cells.
9-It was emphasized that dysplasia should not be assessed in patients receiving growth factors and, furthermore, that, since heavy neutrophil granulation is often the result of sepsis, its presence should not be included in the quantification of dysplastic features for the diagnosis of MDS or for the recognition of multilineage dysplasia in AML. Blast cells that cannot be recognised as belonging to a specific lineage should be designated 'blast, not otherwise categorized'. Assigning lineage to blast cells is facilitated by assessing cells in relation to each other rather than in isolation.
13-Monoblasts and promonocytes should be defined as in the WHO classification 6 . A monoblast has a round or oval nucleus. A promonocyte has a convoluted, folded or grooved nucleus. In the WHO classification, a promonocyte is a blast equivalent and the term should therefore be applied only to a cell that has a delicate or dispersed chromatin pattern, equivalent to that of a monoblast.
Distinction between a monoblast and a promonocyte is not of practical importance since they are regarded as having the same significance. However, distinction between a promonocyte and an atypical/abnormal/immature monocyte can be very difficult. A lack of rigour in applying the defining criteria of promonocyte definition may lead to monocytes being misclassified as promonocytes, which could in turn lead to an erroneous assessment of the number of blasts plus blast equivalents and thus to a misdiagnosis of chronic myelomonocytic leukaemia as acute monocytic leukaemia.
Appreciation of the immature chromatin pattern is crucial in recognition of a cell of monocyte lineage as a blast equivalent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w Table 3 . Morphological cell-term options of 79 cells showing a scoring difference <7 between 2 options after the Delphi round (the first option is the quoted one).
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Series/Subgroups Cells Cell-term options
Granulocytic (26) promyelocyte (16) myelocyte (1) metamyelocytes (2) neutrophil (4) mast cell (3) dysplastic vs normal (7) dysplastic vs blast (1) abnormal vs blast (2) abnormal vs promyelocyte, abnormal, hypergranular (2) promyelocyte vs promyelocyte, hypergranular (2) promyelocyte vs to delete (1) promyelocyte vs myelocyte (1) myelocyte, eosinophilic, dysplastic vs metamyelocyte, eosinophilic (1) metamyelocyte, eosinophilic vs myelocyte, eosinophilic (1) metamyelocyte, dysplastic, pseudo-Pelger vs metamyelocyte, dysplastic (1) dysplastic vs normal (3) dysplastic vs apoptotic (1) atypical vs normal (3) Erythroid (9) basophilic (1) polychromatic (6) orthochromatic (1) promegaloblast (1) dysplastic vs normal (8) promegaloblast vs erythroblast basophilic (early) megaloblastic (1) Monocytic ( Lymphoid (16) lymphocyte (5) plasma cells (11) lymphocyte vs lymp, villous (1) cleaved vs prolymphocyte (1) atypical vs to delete (2) LGL vs to delete (1) dysplastic vs atypical (9) atypical vs plasmablast (1) atypical vs to delete (1) Blast (6) blast (6) blast vs monoblast (2) blast vs promonocyte (2) blast vs promyelocyte (1) blast vs blast, peroxydase negative (1) Megakaryocytic (3) Megakaryocyte (2) megakaryoblast (1) dysplastic vs normal (2) megakaryoblast vs micromegakaryoblast (1) Other (1) histiocyte (1) histiocyte, malignant histiocytosis vs hystiocyte, immature
To delete (6) to delete to delete vs: smear cell (1), blast (3), plasma cell immature (1), erythroblast dysplastic (1), mast cell (1) Table 4 The second phase of study: Distribution of the submitted cell lineage before and after the discussion at the meeting in Nancy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Cell distribution
